Archiv
Archiv anzeigen:
bis


Long-Term Effects of Repeat Hepatectomy vs. Percutaneous Radiofrequency Ablation for Hepatocellular Cancer

David H. Ilson, MD, PhD reviewing Xia Y et al. JAMA Oncol 2019 Nov 27

Overall survival was not significantly different with repeat hepatectomy than with RFA.


Gene Therapy for Patients with Hemophilia A

Brady L. Stein, MD, MHS reviewing Pasi KJ et al. N Engl J Med 2020 Jan 2

Sustained clinical benefit and safety were observed following administration of adeno-associated virus–mediated factor VIII therapy.


New, Unconfirmed Bone Lesions in Prostate Cancer Patients Receiving Enzalutamide

Robert Dreicer, MD, MS, MACP, FASCO reviewing Armstrong AJ et al. JAMA Oncol 2019 Dec 12, Swami U et al. JAMA Oncol 2019 Dec 12

New lesions on posttreatment scans may represent pseudoprogression and should not necessarily trigger discontinuation of enzalutamide in docetaxel-naive men with metastatic disease.


NEJM Journal Watch Oncology and Hematology Top Stories of 2019

William J. Gradishar, MD

Highlights of the most important research in the field from the past year


Subsequent Lumpectomy and Partial-Breast Irradiation for Breast Cancer Recurrence

Benjamin D Smith, MD reviewing Arthur DW et al. JAMA Oncol 2019 Nov 21

Risk for in-breast recurrence was reassuringly low through 5 years of follow-up.


Colorectal Cancer Screening in Asymptomatic Average-Risk Adults

Daniel D. Dressler, MD, MSc, SFHM, FACP reviewing Qaseem A et al. Ann Intern Med 2019 Nov 5

The American College of Physicians reconciles various published guidelines in its guidance statement for colorectal cancer screening.


Do Women with Extremely Dense Breasts Benefit from Supplemental MRI Screening?

Laila Samiian, MD, FACS reviewing Bakker MF et al. N Engl J Med 2019 Nov 28

Breast MRI detected more cancers but also led to more biopsies that were benign.


Breast Cancer May Be Biologically Different in Men Than in Women

William J. Gradishar, MD reviewing Wang F et al. JAMA Oncol 2019 Sep 19

Even after controlling for multiple factors, 3-year mortality was 15% higher in men.


Vistusertib for ER-Positive Breast Cancer

William J. Gradishar, MD reviewing Schmid P et al. JAMA Oncol 2019 Nov, Unni N and Arteaga CL. JAMA Oncol 2019 Nov

Adding the dual-mTORC inhibitor vistusertib to fulvestrant failed to improve progression-free survival.


Archiv
Seite von 88
Editorial Member Board Empfehlungen

Dr. med. Richard Herrmann

Prof. em. für Onkologie Universitätsspital Basel

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

Die Zahl der veröffentlichten Studien, die für die Betreuung unserer Tumorpatienten von Bedeutung sind, ist kaum mehr überschaubar. Hier hilft uns die Selektion des Teams von Journal Watch. Mit dieser neuen Serie soll eine weitere Auswahl getroffen werden. Diese ist, wie wohl auch die vorgenannte, nicht ohne Subjektivität. Für die Auswahl wichtig war mir ganz besonders die Praxisrelevanz.

Kommentar weiterlesen

Apalutamide for Castration-Resistant PSA-Only Prostate Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Smith MR et al. N Engl J Med 2018 Feb 8

Metastasis-free survival was significantly longer with apalutamide than with placebo.


Second-Line Olaparib for Gastric Cancer

David H. Ilson, MD, PhD reviewing Bang Y-J et al. Lancet Oncol 2017 Dec

Contrary to prior findings, adding olaparib to paclitaxel failed to improve survival in patients with disease progression following chemotherapy.


Predicting Response to Immunotherapy in Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Rizvi H et al. J Clin Oncol 2018 Jan 16

Assessment of tumor mutation burden using targeted next-generation sequencing may be predictive of benefit from PD-1 and PD-L1 inhibitors.


Prolonged Adjuvant Aromatase Inhibitor Treatment for Early Breast Cancer

William J. Gradishar, MD reviewing Blok EJ et al. J Natl Cancer Inst 2018 Jan 1, Goldvaser H et al. J Natl Cancer Inst 2018 Jan 1, Pohlmann PR and Isaacs C. J Natl Cancer Inst 2018 Jan 1

Outcomes were not superior with 5 versus 2.5 years of extended letrozole therapy.


Prognosis of Monoclonal Gammopathy of Undetermined Significance

David Green, MD, PhD reviewing Kyle RA et al. N Engl J Med 2018 Jan 18

Overall survival was significantly shorter among MGUS patients than among a matched control population in a long-term follow-up study.


Prognosis for BRCA-Mutated Breast Cancer

William J. Gradishar, MD reviewing Copson ER et al. Lancet Oncol 2018 Jan 11

Survival is similar between BRCA mutation carriers versus those with sporadic disease.


Electrical Field Therapy for Glioblastoma

Roy E. Strowd, MD reviewing Stupp R et al. JAMA 2017 Dec 19

Adding tumor-treating electrical-field therapy to maintenance temozolomide chemotherapy significantly improved survival in patients with newly diagnosed glioblastoma.


Atezolizumab for Advanced Urothelial Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Powles T et al. Lancet 2017 Dec 18, Massari F and Di Nunno V. Lancet 2017 Dec 18

Overall survival was not improved with the PD-L1 inhibitor atezolizumab versus chemotherapy in patients with highest PD-L1 expression.


Pembrolizumab for Cisplatin-Ineligible Patients with Advanced Urothelial Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Balar AV et al. Lancet Oncol 2017 Sep 26

First-line therapy demonstrated antitumor activity in a phase II study.


Restarting Adjuvant Endocrine Therapy for Breast Cancer

William J. Gradishar, MD reviewing He W et al. J Natl Cancer Inst 2017 Oct 01

Disease-free survival is significantly improved in patients who restart therapy versus those who do not restart after discontinuation.